Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

NCT03935334 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A or B With Inhibitor

Interventions

BIOLOGICAL: Biosimilar eptacog alfa, activated (AryoSeven)
BIOLOGICAL: Eptacog alfa, activated (Novoseven)

Sponsor

AryoGen Pharmed Co.